ValuEngine Lowers CTI BioPharma Corp. (CTIC) to Strong Sell
CTI BioPharma Corp. (NASDAQ:CTIC) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Wednesday.
Separately, Jefferies Group LLC began coverage on CTI BioPharma Corp. in a report on Tuesday, September 12th. They set a “buy” rating and a $7.50 price target on the stock.
Shares of CTI BioPharma Corp. (NASDAQ CTIC) traded down 1.22% on Wednesday, reaching $3.23. 113,983 shares of the company traded hands. The company’s market capitalization is $102.47 million. The firm’s 50 day moving average is $3.26 and its 200 day moving average is $3.62. CTI BioPharma Corp. has a one year low of $2.70 and a one year high of $6.48.
CTI BioPharma Corp. (NASDAQ:CTIC) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.63. The company had revenue of $22.23 million for the quarter. CTI BioPharma Corp. had a negative return on equity of 418.99% and a negative net margin of 136.76%. Analysts expect that CTI BioPharma Corp. will post ($1.26) earnings per share for the current fiscal year.
In related news, Director Richard L. Love sold 14,600 shares of CTI BioPharma Corp. stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $3.21, for a total value of $46,866.00. Following the transaction, the director now directly owns 84,318 shares of the company’s stock, valued at $270,660.78. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.08% of the stock is owned by insiders.
A hedge fund recently bought a new stake in CTI BioPharma Corp. stock. WASHINGTON TRUST Co bought a new position in shares of CTI BioPharma Corp. (NASDAQ:CTIC) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 31,400 shares of the biopharmaceutical company’s stock, valued at approximately $104,000. WASHINGTON TRUST Co owned 0.11% of CTI BioPharma Corp. as of its most recent SEC filing. Institutional investors and hedge funds own 42.87% of the company’s stock.
CTI BioPharma Corp. Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.